{"title":"罗氏83亿美元收购InterMune获得特发性肺纤维化药物吡非尼酮","authors":"Heather Cartwright","doi":"10.3833/PDR.V2014I9.2063","DOIUrl":null,"url":null,"abstract":"In its fifth M&A deal of 2014 so far, Roche has agreed to buy its former partner InterMune for approximately US$8.3 B in an all-cash deal, the company’s largest since its US$46.8 B purchase of 44% of Genentech in 2009. With the acquisition, Roche will gain InterMune’s idiopathic pulmonary fibrosis drug pirfenidone, which is approved in Europe and Canada as Esbriet® and which is awaiting a regulatory decision in the US. The deal will expand Roche’s small respiratory franchise, which include Pulmozyme® (dornase alpha) for cystic fibrosis and Xolair® (omalizumab) for allergic asthma.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"15 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2014-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Roche to Buy InterMune for US$8.3 B to Gain Pirfenidone for Idiopathic Pulmonary Fibrosis\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2014I9.2063\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In its fifth M&A deal of 2014 so far, Roche has agreed to buy its former partner InterMune for approximately US$8.3 B in an all-cash deal, the company’s largest since its US$46.8 B purchase of 44% of Genentech in 2009. With the acquisition, Roche will gain InterMune’s idiopathic pulmonary fibrosis drug pirfenidone, which is approved in Europe and Canada as Esbriet® and which is awaiting a regulatory decision in the US. The deal will expand Roche’s small respiratory franchise, which include Pulmozyme® (dornase alpha) for cystic fibrosis and Xolair® (omalizumab) for allergic asthma.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"15 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-09-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2014I9.2063\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2014I9.2063","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Roche to Buy InterMune for US$8.3 B to Gain Pirfenidone for Idiopathic Pulmonary Fibrosis
In its fifth M&A deal of 2014 so far, Roche has agreed to buy its former partner InterMune for approximately US$8.3 B in an all-cash deal, the company’s largest since its US$46.8 B purchase of 44% of Genentech in 2009. With the acquisition, Roche will gain InterMune’s idiopathic pulmonary fibrosis drug pirfenidone, which is approved in Europe and Canada as Esbriet® and which is awaiting a regulatory decision in the US. The deal will expand Roche’s small respiratory franchise, which include Pulmozyme® (dornase alpha) for cystic fibrosis and Xolair® (omalizumab) for allergic asthma.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
